PuriCore PLC Receives FDA Clearance for Vashe Skin and Wound Hydrogel

PuriCore PLC (PuriCore) announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market a new hydrogel formulation of its Vashe technology. The new Vashe Skin and Wound Hydrogel is indicated for the management and relief of pain, burning, and itching experienced with various dermatoses including atopic dermatitis. PuriCore intends to use this hydrogel clearance to advance new product development and partnering opportunities in dermatology, wound care, and animal health. PuriCore estimates that these three markets in total comprise annual sales of $30 billion in the US.